Ghazi Lama, Drawz Paul
Division of Renal Disease and Hypertension, Department of Medicine, University of Minnesota, Minnesota, MN, USA.
F1000Res. 2017 Mar 21;6. doi: 10.12688/f1000research.9692.1. eCollection 2017.
The renin-angiotensin-aldosterone system (RAAS) plays a fundamental role in the physiology of blood pressure control and the pathophysiology of hypertension (HTN) with effects on vascular tone, sodium retention, oxidative stress, fibrosis, sympathetic tone, and inflammation. Fortunately, RAAS blocking agents have been available to treat HTN since the 1970s and newer medications are being developed. In this review, we will (1) examine new anti-hypertensive medications affecting the RAAS, (2) evaluate recent studies that help provide a better understanding of which patients may be more likely to benefit from RAAS blockade, and (3) review three recent pivotal randomized trials that involve newer RAAS blocking agents and inform clinical practice.
肾素-血管紧张素-醛固酮系统（RAAS）在血压控制生理及高血压（HTN）病理生理过程中发挥着重要作用，对血管张力、钠潴留、氧化应激、纤维化、交感神经张力及炎症均有影响。幸运的是，自20世纪70年代以来就有RAAS阻断剂可用于治疗高血压，并且新型药物也在不断研发中。在本综述中，我们将：（1）研究影响RAAS的新型抗高血压药物；（2）评估近期有助于更好地理解哪些患者可能更易从RAAS阻断中获益的研究；（3）回顾三项近期涉及新型RAAS阻断剂的关键随机试验，并为临床实践提供参考。
